RecruitingPhase 2NCT06132178
Psilocybin rTMS for Treatment Resistant Depression
Studying Mal de débarquement
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Texas at Austin
- Principal Investigator
- Gregory A Fonzo, Ph.D.The University of Texas at Austin
- Intervention
- Psilocybin(drug)
- Enrollment
- 100 target
- Eligibility
- 22-65 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06132178 on ClinicalTrials.govOther trials for Mal de débarquement
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07422844Dynamic Network Response to TMS TreatmentGoethe University
- ENROLLING BY INVITATIONNCT06512324Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness RegistryBiomedical Discoveries and Neuroscientific Foundations LLC
- RECRUITINGNANCT05460520DevRobust Treatment for Mal de Débarquement SyndromeIcahn School of Medicine at Mount Sinai